Athena Athena

X
[{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"MC2 Therapeutics Announces Collaboration with EPI Health on Commercialization of Newly Approved Psoriasis Drug, WYNZORA\u00ae Cream, in the US","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2020","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"EPI Health","sponsor":"MC2 Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA\u00ae (calcipotriene and betamethasone dipropionate) Cream, 0.005%\/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"},{"orgOrder":0,"company":"EPI Health","sponsor":"Novan","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Novan and EPI Health, a Novan Company, Announce Abstracts Accepted for Poster Presentation at the 42nd Annual Fall Clinical Dermatology Conference\u00ae","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"EPI Health","sponsor":"Sato Yakuhin Kogyo Co., Ltd","pharmaFlowCategory":"D","amount":"$7.5 million","upfrontCash":"$5.0 million","newsHeadline":"EPI Health, a Novan Company, Enters into Exclusive License Agreement with Sato Pharmaceutical Co., Ltd. for RHOFADE\u00ae in Japan","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2022","url1":"","url2":"","graph1":"Dermatology","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by EPI Health

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            Rhofade (oxymetazoline hydrochloride) cream is an FDA-approved prescription topical treatment that may reduce persistent facial redness by at least two grades, according to both doctor and patient scales that evaluated rosacea redness in two 29-day trials in adults.

            Lead Product(s): Oxymetazoline Hydrochloride

            Therapeutic Area: Dermatology Product Name: Rhofade

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Sato Yakuhin Kogyo Co., Ltd

            Deal Size: $7.5 million Upfront Cash: $5.0 million

            Deal Type: Licensing Agreement December 21, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            WYNZORA Cream is a fixed dose combination of calcipotriene and betamethasone dipropionate used for the topical treatment of plaque psoriasis. Betamethasone dipropionate has anti-inflammatory effects resulting in decreased expression of key TNF-α, IL-17A/F and IL-23 cytokines.

            Lead Product(s): Berdazimer Sodium

            Therapeutic Area: Infections and Infectious Diseases Product Name: SB206

            Highest Development Status: Phase III Product Type: Small molecule

            Recipient: Novan

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            WYNZORA is a cream-based fixed dose combination of calcipotriene and betamethasone dipropionate for topical treatment of plaque psoriasis. It is based on PAD™ Technology, which enables stability of both calcipotriene and betamethasone dipropionate in aqueous formulation.

            Lead Product(s): Calcipotriol,Betamethasone Dipropionate

            Therapeutic Area: Dermatology Product Name: Wynzora

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: MC2 Therapeutics

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable September 15, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Collaboration accelerates a Q1 2021 comprehensive launch of MC2’s WYNZORA® Cream to patients with plaque psoriasis in the US. WYNZORA® Cream is the first drug based on PADTM Technology – providing innovative solutions to unmet needs in chronic inflammatory conditions.

            Lead Product(s): Calcipotriol,Betamethasone Dipropionate

            Therapeutic Area: Dermatology Product Name: Wynzora

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: MC2 Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration August 24, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY